Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Ascendis Pharma A/S logo

Ascendis Pharma A/S (ASND) Stock Ticker

NASDAQ: ASND · Healthcare · Biotechnology
$230.02-2.21%
USD · as of 2026-09-28 · market cap $14.0B
Open ASND in TickrDownload for iPhone

ASND right now

Growing revenue 63% a year on 90% gross margins.
Options expect by Oct 6±6.2%
Options expect by Oct 29±12.7%
Priced in for Nov 11 earnings±15.3%
IV rank (30-day)53% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full ASND picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on ASND
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

ASND stock facts

Ticker symbolASND
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$14.0B
CEOJan Moller Mikkelsen
Employees1,189
HeadquartersHellerup, CR, DK
IPO date2015-01-28
Websiteascendispharma.com

What you can see for ASND on Tickr

Live ASND price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ASND report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Ascendis Pharma A/S?

The ticker symbol for Ascendis Pharma A/S is ASND, listed on the NASDAQ Global Select.

What is ASND?

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates.…

HomeExploreMarketLists
All pages